Preface |
|
ix | |
Acknowledgments |
|
xi | |
|
Chapter 1 Laying the Groundwork |
|
|
1 | (26) |
|
Background for Evidence-Based ADA Guidelines for Standards of Diabetes Care |
|
|
|
|
|
|
|
|
|
|
|
|
|
Peripheral Neuropathy and Foot Examination |
|
|
|
|
|
|
|
Rationale for Using Treatment Algorithms |
|
|
|
Chapter 2 Evidence-Based Principles of Nonpharmacological Therapy |
|
|
27 | (18) |
|
Diabetes Self-Management Education and Support (DSME/DSMS) |
|
|
|
Medical Nutrition Therapy |
|
|
|
Total Calories and Weight Control |
|
|
|
|
|
|
|
|
|
Overall Macronutrient Composition |
|
|
|
Micronutrients, Alcohol, and Dietary Supplements |
|
|
|
|
|
|
45 | (56) |
|
|
|
|
|
|
|
Metformin (Glucophage, Glumetza) |
|
|
|
Sulfonylurea Agents and Glinides |
|
|
|
Thiazolidinediones (Glitazones) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Treatment of Markedly Symptomatic, Newly Diagnosed Patients with Type 2 Diabetes |
|
|
|
|
|
Self-Monitoring of Blood Glucose |
|
|
|
|
|
|
|
Principles of Adjusting Insulin Doses |
|
|
|
Multiple-Injection Insulin Regimens: General Considerations |
|
|
|
|
101 | (22) |
|
Hypercholesterolemia and ASCVD |
|
|
|
Principles of Hypercholesterolemia Treatment |
|
|
|
Hypertriglyceridemia and ASCVD |
|
|
|
Hypertriglyceridemia and Pancreatitis |
|
|
|
Principles of Hypertriglyceridemia Treatment |
|
|
|
|
|
|
123 | (28) |
|
Hypertension and Diabetes Complications |
|
|
|
Principles of Hypertension Treatment |
|
|
|
|
|
Angiotensin Receptor Blockers (ARBs) |
|
|
|
Thiazide and Loop Diuretics |
|
|
|
|
|
|
|
β-Adrenergic Receptor Antagonists (β-Blockers) |
|
|
|
Aldosterone Receptor Antagonists (Potassium-Sparing Diuretics) |
|
|
|
|
|
α2-Adrenergic Receptor Agonists (Central and Peripheral Sympatholytics) |
|
|
|
α1-Adrenergic Receptor Antagonists (α-Blockers) |
|
|
|
|
Appendix: Self-Titration Instructions for Patients |
|
151 | (4) |
English Version |
|
Spanish Version |
|
Index |
|
155 | |